Arrowstreet Capital
CYTK icon

Arrowstreet Capital’s Cytokinetics CYTK Stock Holding History

Arrowstreet Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-31,170
Closed -$648K – 2292
2020
Q4 		$648K Buy
+31,170
New +$570K ﹤0.01% 1950
2020
Q1 		– Sell
-72,100
Closed -$765K – 1910
2019
Q4 		$765K Buy
+72,100
New +$741K ﹤0.01% 1403
2016
Q2 		– Sell
-35,912
Closed -$253K – 1359
2016
Q1 		$253K Hold
35,912
– – ﹤0.01% 1232
2015
Q4 		$376K Buy
+35,912
New +$352K ﹤0.01% 1201
2014
Q1 		– Sell
-119,066
Closed -$774K – 1181
2013
Q4 		$774K Sell
119,066
-40,005
-25% -$263K ﹤0.01% 882
2013
Q3 		$1.21M Buy
+159,071
New +$1.71M 0.01% 627

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Arrowstreet Capital's CYTK Position: Q1 2021 in Review

Arrowstreet Capital sold out of Cytokinetics (CYTK) in Q1 2021, closing a stake of 31,170 shares — an estimated $648K sold.

Arrowstreet Capital first reported a position in CYTK in Q3 2013 and held it in 6 quarters. The position peaked at $1.21M in Q3 2013. 192 funds tracked by Wall St. Rank hold CYTK as of Q1 2021.

  • Arrowstreet Capital reported no remaining Cytokinetics position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 31,170 Cytokinetics shares in Q1 2021, an estimated $648K.
  • Arrowstreet Capital first reported a position in Cytokinetics in Q3 2013 and held it in 6 quarters.
  • Arrowstreet Capital's Cytokinetics position peaked at $1.21M in Q3 2013.
  • 192 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.